Mitomycin plus Vindesine and Cispltin in patients with Non-small cell lung cancer

Objective: Observe the therapeutic effects and toxicity reaction of MVP regimen for the treatment of non-small cell lung cancer (NSCLC). Methods: 45 cases were treated with MVP (MMC +VDS +DDP) regimen. Results: Response rates were 46.7 % (21/45). Neutropeniawas the dose-limited toxicity and was occurred in 75.6 % of cases. No other serious side reaction occurred in all patients. Conclusions: There was definitive good therapeutic effect but slight side reaction with MVP regimen in the treatment of NSCLC.